Sino Biopharmaceutical Ltd (1177.HK) stock: key figures, P/E, revenue and dividend
Health Care · Hong Kong · ISIN KYG8167W1380
Sino Biopharmaceutical Ltd financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 28.87 bn CNY | 32.05 bn CNY |
| Gross profit | 23.53 bn CNY | 26.31 bn CNY |
| EBIT | 6.14 bn CNY | 7.00 bn CNY |
| Net income | 3.50 bn CNY | 2.36 bn CNY |
| Diluted EPS – continuing operations | 0.19 CNY | 0.13 CNY |
Full history since 1999, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Sino Biopharmaceutical Ltd
Sino Biopharmaceutical Limited, an investment holding company, operates as a research and development pharmaceutical conglomerate in the People's Republic of China. It operates through three segments: Modernised Chinese Medicines and Chemical Medicines, Investment, and Others. The company offers oncology medicines, including anlotinib hydrochloride capsules under Focus V brand, penpulimab injection under Annike brand, efbemalenograstin alfa injection under Yilishu brand, benmelstobart injection under Andewei brand, unecritinib fumarate capsules under Anboni brand, envonalkib citrate capsule under Anluoqing brand, garsorasib tablets under Anfangning brand, bevacizumab injection under Anbeisi brand, culmerciclib capsule under Saitanxin brand, zongertinib tablets under Hernexeos brand, rovadicitinib tablet under Anxu brand,rituximab injection under Delituo brand, trastuzumab for injection under Saituo brand, and pertuzumab injection, under Paletan brand; liver disease medications, such as magnesium isoglycyrrhizinate injection under Tianqing Ganmei brand and entecavir dispersible tablets under Runzhong brand; and respiratory system medicines comprising budesonide suspension for inhalation under Tianqing suchang brand. It also provides surgery/analgesia medicines, including flurbiprofen cataplasms under the brand Zepolas, limaprost tablets under the brand Kailitong, and recombinant human coagulation factor VIII for injection under the brand Anqixin. In addition, the company develops liver disease drugs, such as Lanifibranor and TQA2225; respiratory system drugs comprising TDI01, TQC2731, TCR1672, TQC3721, and TQH3906; and surgery/analgesia drugs, including PL-5, an antimicrobial peptide, TRD205, an AT2R inhibitor, and TRD208. Further, it is involved in the long-term investments; and healthcare and hospital business. The company was incorporated in 2000 and is headquartered in Wan Chai, Hong Kong.
More stocks
- Mora Telematika Indonesia (MORA.JK)
- Smith & Nephew PLC (SN.L)
- CROWN HOLDINGS, INC. (CCK)
- Summit Therapeutics Inc. (SMMT)
- McCormick & Company (MKC)
- Zhejiang Juhua Co Ltd (600160.SS)
- Erie Indemnity (ERIE)
- Jiangsu Wujiang China Eastern Silk Market Co Ltd (000301.SZ)
- Toll Brothers, Inc. (TOL)
- Universal Health Services (UHS)
- Xian LONGi Silicon Materials Corp (601012.SS)
- Bunzl plc (BNZL.L)
Not investment advice. All data without warranty, price as of 15.10.2026. Details in the risk notice.